Insights and future directions of potential genetic therapy for Apert syndrome: A systematic review
- 22 February 2021
- journal article
- review article
- Published by Springer Nature in Gene Therapy
- Vol. 28 (10-11) , 620-633
Abstract
Apert syndrome is a genetic disorder characterised by craniosynostosis and structural discrepancy of the craniofacial region as well as the hands and feet. This condition is closely linked with fibroblast growth factor receptor-2 (FGFR2) gene mutations. Gene therapies are progressively being tested in advanced clinical trials, leading to a rise of its potential clinical indications. In recent years, research has made great progress in the gene therapy of craniosynostosis syndromes and several studies have investigated its influences in preventing/diminishing the complications of Apert syndrome. This article reviewed and exhibited different techniques of gene therapy and their influences in Apert syndrome progression. A systematic search was executed using electronic bibliographic databases including PubMed, EMBASE, ScienceDirect, SciFinder and Web of Science for all studies of gene therapy for Apert syndrome. The primary outcomes measurements vary from protein to gene expressions. According to the findings of included studies, we conclude that the gene therapy using FGF in Apert syndrome was critical in the regulation of suture fusion and patency, occurred via alterations in cellular proliferation. The superior outcome could be brought by biological therapies targeting the FGF/FGFR signalling. More studies in molecular genetics in Apert syndrome are recommended. This study reviews the current literature and provides insights to future possibilities of genetic therapy as intervention in Apert syndrome.Keywords
This publication has 41 references indexed in Scilit:
- Study of environmental and genetic factors in children with craniosynostosis: A case-control studyJournal of Pediatric Neurosciences, 2013
- FGFR2 Mutation Confers a Less Drastic Gain of Function in Mesenchymal Stem Cells Than in FibroblastsStem Cell Reviews and Reports, 2011
- Identification and characterization of an inhibitory fibroblast growth factor receptor 2 (FGFR2) molecule, up-regulated in an Apert Syndrome mouse modelBiochemical Journal, 2011
- Craniosynostosis genetics: The mystery unfoldsIndian Journal of Human Genetics, 2011
- Increased EFG- and PDGF -receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosisHuman Molecular Genetics, 2010
- Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformationsProceedings of the National Academy of Sciences, 2009
- Medical treatment of craniosynostosis: recombinant Noggin inhibits coronal suture closure in the rat craniosynostosis modelOrthodontics & Craniofacial Research, 2009
- Gene therapy and its implications in PeriodonticsJournal of Indian Society of Periodontology, 2009
- RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosisNature Genetics, 2007
- Principles of gene therapyIndian Journal of Dental Research, 2007